ConductScience.org, home

Paper24980665

Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus.

Ferdinand KC and 9 others. Hypertension, 2014. Cited by 123 papers, by iCite.

Cite this record

ConductScience Library. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Papers, record 24980665. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24980665

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus.
PubMed
Journal
Hypertension
PubMed
Year
2014
PubMed
Publication types
Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
123
iCite
Relative citation ratio, by iCite
3.9
iCite
Revised in PubMed
2026-01-28
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ferdinand KCKeith C
2White WBWilliam B
3Calhoun DADavid A
4Lonn EMEva M
5Sager PTPhilip T
6Brunelle RRocco
7Jiang HHHonghua H
8Threlkeld RJRebecca J
9Robertson KEKenneth E
10Geiger MJMary Jane

Source PubMed

Download CSV of authors

Topics23

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Blood PressureMajor topic
Diabetes Mellitus, Type 2Major topic
Glucagon-Like PeptidesMajor topic
Heart RateMajor topic
Immunoglobulin Fc FragmentsMajor topic
Receptors, GlucagonMajor topic
Recombinant Fusion ProteinsMajor topic
Aged
Blood Pressure Monitoring, Ambulatory
Diarrhea
Double-Blind Method
Drug Administration Schedule
Female
Glucagon-Like Peptide-1 Receptor
Glycated Hemoglobin
Humans
Hypoglycemic Agents
Injections, Subcutaneous
Male
Middle Aged
Nausea
Treatment Outcome
Vomiting

Source PubMed

Download CSV of topics

Cited by72

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 123 citations.

PMIDTitleJournalYearIn PapersSource
42830469Glucagon-Like Peptide-1 Agonists and Blood Pressure Regulation: Molecular Mechanisms and Cardiovascular Implications.Pharmacol Res Perspect2026https://conductscience.org/library/papers/42830469PubMed
42750018Efficacy and safety of orforglipron 12 mg versus orforglipron 36 mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysis.BMC Endocr Disord2026https://conductscience.org/library/papers/42750018PubMed
42719822GLP-1 receptor agonists in cardiovascular disease: a guide for cardiologists.Br J Cardiol2026https://conductscience.org/library/papers/42719822PubMed
42380521Contractile effects of dulaglutide in the human atrium.Naunyn Schmiedebergs Arch Pharmacol2026https://conductscience.org/library/papers/42380521PubMed
42365335Comparative cardiovascular efficacy of antidiabetic therapies in type 2 diabetes: a systematic review and network meta-analysis of randomized trials.Diabetol Metab Syndr2026https://conductscience.org/library/papers/42365335PubMed
42076099Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart.Pharmaceutics2026https://conductscience.org/library/papers/42076099PubMed
41489846Exploring the rates of Gastrointestinal adverse effects among five GLP-1 receptor agonists: A systematic review and Meta-Analysis of randomized controlled trials.Endocrine2026https://conductscience.org/library/papers/41489846PubMed
41425685New-Onset Atrial Fibrillation Potentially Associated With Tirzepatide: A Case Report.Cureus2025https://conductscience.org/library/papers/41425685PubMed
41378487Glucagon-Like Peptide-1 Receptor Agonists Versus Bariatric Surgery in Patients With Obesity and Heart Failure With Preserved Ejection Fraction.J Am Heart Assoc2025https://conductscience.org/library/papers/41378487PubMed
41324724Blood Pressure-Lowering Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists.Curr Hypertens Rep2025https://conductscience.org/library/papers/41324724PubMed
41102420Possible mechanisms of action of glucagon-like peptide-1 receptor agonists on blood pressure beyond body weight.Hypertens Res2025https://conductscience.org/library/papers/41102420PubMed
41050409Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis.Front Pharmacol2025https://conductscience.org/library/papers/41050409PubMed
40458885Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome.Future Cardiol2025https://conductscience.org/library/papers/40458885PubMed
40214900Efficacy and Safety of Tirzepatide Compared with GLP-1 RAs in Patients with Type 2 Diabetes Treated with Basal Insulin: A Network Meta-analysis.Diabetes Ther2025https://conductscience.org/library/papers/40214900PubMed
39954057Different formulations of semaglutide and oxidative stress in subjects with type 2 diabetes and MASLD: an open-label, real-life study.Acta Diabetol2025https://conductscience.org/library/papers/39954057PubMed
39217384The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension.Clin Hypertens2024https://conductscience.org/library/papers/39217384PubMed
39145614GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms.J Endocrinol2024https://conductscience.org/library/papers/39145614PubMed
39071115Chronic kidney disease combined with metabolic syndrome is a non-negligible risk factor.Ther Adv Endocrinol Metab2024https://conductscience.org/library/papers/39071115PubMed
38983582The Global Burden of Resistant Hypertension and Potential Treatment Options.Eur Cardiol2024https://conductscience.org/library/papers/38983582PubMed
38766425Cardioprotective effects of glucagon-like peptide 1 receptor agonists in heart failure: Myth or truth?World J Diabetes2024https://conductscience.org/library/papers/38766425PubMed

See all 72 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
GLP1R2740PubTator's text mininghttps://conductscience.org/library/genes/2740

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/24980665

GET https://conductscience.org/api/papers/v1/24980665/cited_by?page=2